MeSH tree: C04.557.470.615.275
Cancer cell movement during metastasis is a dynamic process regulated by several different signals. However, the way cells receive, process and respond to these signals has been extremely hard to detect, but is now made easier ...
Jun 2, 2025
0
23
A drug already approved by the FDA to treat menopause symptoms may also help prevent invasive breast cancer, according to new findings from a multi-center phase 2 clinical trial led by Northwestern Medicine.
May 29, 2025
0
32
For women at higher risk of breast cancer, there is a proven way to cut the risk in half: take an anti-cancer drug such as tamoxifen.
May 29, 2025
0
14
Women who experience significant weight gain after the age of 20 and either have their first child after the age of 30 or don't have children are almost three times more likely to develop breast cancer than those who give ...
May 9, 2025
0
47
At 71, Tina Knowles—the fashion designer, businesswoman, and mother of Beyoncé—made headlines not for her career, but for a deeply personal revelation: her breast cancer diagnosis. In 2023, a routine mammogram uncovered two ...
Apr 29, 2025
0
18
By assessing how "sticky" tumor cells are, researchers at the University of California San Diego have found a potential way to predict whether a patient's early-stage breast cancer is likely to spread. The discovery, made ...
Mar 5, 2025
0
15
New research results now published from Lund University's MASAI trial are even better than the initial findings from last year: AI-supported breast screening detected 29% more cases of cancer compared with traditional screening. ...
Feb 4, 2025
0
36
Some early breast cancer patients can safely avoid specific surgeries, according to two studies exploring ways to lessen treatment burdens.
Dec 12, 2024
0
14
Patients with low-risk ductal carcinoma in situ (DCIS) who underwent active monitoring reported comparable physical, emotional, and psychological outcomes to patients who received upfront treatment, according to results from ...
Dec 12, 2024
0
15
Among patients with hormone receptor (HR)-positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS), those who underwent active monitoring had similar two-year invasive ipsilateral breast cancer recurrence rates as ...
Dec 12, 2024
0
10
